Comparing Oncobiologics (NASDAQ:OTLK) and Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Valuation & Earnings

This table compares Celldex Therapeutics and Oncobiologics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celldex Therapeutics $158,000.00 14,194.86 -$258.76 million ($4.30) -6.64
Oncobiologics -$1.16 million -82.86 -$62.42 million ($0.77) -0.51

Oncobiologics has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Celldex Therapeutics and Oncobiologics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics 1 1 11 0 2.77
Oncobiologics 1 2 2 0 2.20

Celldex Therapeutics presently has a consensus target price of $64.08, indicating a potential upside of 124.48%. Oncobiologics has a consensus target price of $5.20, indicating a potential upside of 1,213.13%. Given Oncobiologics’ higher possible upside, analysts clearly believe Oncobiologics is more favorable than Celldex Therapeutics.

Risk and Volatility

Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Profitability

This table compares Celldex Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celldex Therapeutics N/A -52.66% -47.58%
Oncobiologics N/A N/A -254.82%

Institutional and Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Celldex Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.